Clinical effect of Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection in the treatment of severe pneumonia with respiratory failure
FENG Xianrong1 WU Nan1 NIU Weiwei2
1.Department of Respiratory Medicine, Jinzhou Central Hospital, Liaoning Province, Jinzhou 121000, China;
2.Department of Gastroenterology, Jinzhou Central Hospital, Liaoning Province, Jinzhou 121000, China
Abstract：Objective To explore clinical effect and safety of Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection in the treatment of severe pneumonia with respiratory failure. Methods Eighty cases of severe pneumonia patients with respiratory failure admitted to Jinzhou Central Hospital from January 2014 to May 2019 were selected and divided into the control group (40 cases) and the observasion group (40 cases) according to random number table method. The control group was treated with Imipenem and Cilastatin Sodium for Injection, and the observation group was treated with Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection. The two groups were treated for 10 days. Clinical effect was evaluated after treatment. The forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2), oxygenation index (OI), serum procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6) of the two groups were compared. The adverse reactions of the two groups during the treatment were recorded and compared. Results The total effective rate of the observation group was significantly higher than that of the control group (P ＜ 0.05). After treatment, the FEV1, FVC, PEF, PaO2, OI of the two groups were significantly higher than those before treatment (P ＜ 0.05), and PaCO2 was significantly lower than those before treatment (P ＜ 0.05), while FEV1, FVC, PEF, PaO2 and OI in the observation group were significantly higher than those in the control group (P ＜ 0.05), and PaCO2 was significantly lower than that in the control group (P ＜ 0.05). The levels of serum PCT, CRP and IL-6 in the two groups after treatment were significantly lower than those before treatment (P ＜ 0.05), and the levels of serum PCT, CRP and IL-6 in the observation group after treatment were significantly lower than those in the control group (P ＜ 0.05). During treatment, there was no adverse reaction in the two groups. Conclusion Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection in the treatment of severe pneumonia with respiratory failure has a significant effect, which can improve the lung function and blood gas indexes, reduce the serum levels of inflammatory factors, and has good safety.
冯献荣1 吴楠1 牛微微2. 乌司他丁联合注射用亚胺培南西司他丁钠治疗重症肺炎伴呼吸衰竭的临床效果[J]. 中国医药导报, 2020, 17(3): 123-126.
FENG Xianrong1 WU Nan1 NIU Weiwei2. Clinical effect of Ulinastatin combined with Imipenem and Cilastatin Sodium for Injection in the treatment of severe pneumonia with respiratory failure. 中国医药导报, 2020, 17(3): 123-126.
2020, Vol. 17 
京公网安备 11010502046598号